The History of Cystinosis: Lessons for Clinical Management by Goodyer, Paul
SAGE-Hindawi Access to Research
International Journal of Nephrology
Volume 2011, Article ID 929456, 6 pages
doi:10.4061/2011/929456
Review Article
The History of Cystinosis: Lessons for Clinical Management
PaulGoodyer1,2
1Department of Pediatrics, McGill University, Montreal, QC, Canada H3H 1P3
2Montreal Children’s Hospital, 2300 Tupper Street, Montreal, QC, Canada H3H 1P3
Correspondence should be addressed to Paul Goodyer, paul.goodyer@mcgill.ca
Received 6 June 2011; Accepted 1 August 2011
Academic Editor: Michel Fischbach
Copyright © 2011 Paul Goodyer.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cystinosis is a rare disorder, and, accordingly, progress on the understanding and treatment of this disease has been relatively
slow. Although cystinosis was identiﬁed over 100 years ago, the history of cystinosis is marked by a few sudden leaps forward in
our understanding rather than by a sustained research eﬀort fuelled by the larger research community. Major conceptual break-
throughs include (a) its discovery in 1903, (b) recognition of the renal Fanconi syndrome, (c) realization that tissue accumulation
of cystine reﬂects a defective channel in the lysosomal membrane, (d) translation of this discovery to trials of cysteamine, (e)
discovery of the CTNS gene, and (f) report of successful stem cell therapy in the cystinotic mouse. This paper focuses on the
importance management lessons from these milestones and the potential new therapeutic strategies which may be looming in the
near future.
1.CystineAccumulationinCystinosis
Cystinosis as an autosomal recessive disorder caused by
mutations of the CTNS gene on chromosome 17, which
encodes a ubiquitous cystine-speciﬁc transporter (cysti-
nosin) in the lysosomal membrane (Figure 1). Since cysti-
nosin facilitates eﬄux from the lysosome, homozygous
CTNS mutations result in massive intralysosomal accumu-
lation of cystine in crystals which apparently disrupt the
organelle, leading to apoptotic cell death and progressive
organ dysfunction. Over 90 mutations of the CTNS coding
and splice regions have been reported. About half of the
cystinosis alleles in the Western populations are caused by
a 57.2kb deletion which extends from the tenth CTNS exon
throughtheadjacentSHPKandﬁrsttwoexonsoftheTRPV1
(capsaicin receptor) gene ( ). This deletion is thought to have
arisen in Northern Germany in about 500AD.
An unsavoury character from Zurich, Emil Aberhalden’s
scientiﬁc career was described by Otto Westphal as “a fraud
from beginning to end.” Nevertheless, Aberhalden seems to
havebeentheﬁrsttoidentifycystinosis.In1903,hedescribed
a child with severe growth failure in infancy who had
cystine crystals in the liver and spleen at autopsy [1]. Tissue
accumulation of cystine remains the diagnostic hallmark of
cystinosis. Elevation of cystine can be quantiﬁed directly
from chorionic villus samples at week 9-10 of gestation or
c a nb em e a s u r e di nf e t a lc e l l sf r o ma m n i o t i cﬂ u i dp r i o rt o
20 weeks of gestation (Jackson Prenatal Dx 2005). At birth,
placentalcystine(2–5umoles/gprotein)iswellabovenormal
(0.1–0.2umoles/gprotein).Althoughcornealcrystalsmaybe
seen with a slit lamp by about 1 year of age, these deposits
representcoalescenceofextracellularcystineleftbyapoptotic
cells and may not be present at birth. As infants develop
growth failure at 4–6 months of age, diagnostic elevation
of cystine levels can be measured in circulating leukocytes.
However, the absolute level of leukocyte cystine varies
appreciably from laboratory to laboratory, and lymphocyte
cystine(5Xnormal)islowerthanthatinpolymorphonuclear
leukocytes. Since results are expressed as micromoles of
cystine per mg cellular protein in the sample, variability in
the reported leukocyte cystine level depends, in large part,
on how the white cells are isolated at the point of care,
rather than from variation induced by the method of cystine
measurement (cystine binding assay, automated amino acid
analyzer, or HPLC). To minimize variation, the University of
California at San Diego has published a protocol for leuko-
cyteisolation(http://biochemgen.ucsd.edu/cystinosis/).This
protocol emphasizes prompt leukocyte separation by mixing
blood with an equal volume of acid-citrate-dextran solution,
allowing the red blood cells to settle by gravity for one















Figure 1: (a) Depiction of CTNS protein spanning the lysosomal
membrane, (b) the common 57.2kb deletion extending upstream
from CTNS exon 10 through the ﬁrst two exons of TRPV1.
lysed; the sample is acidiﬁed and frozen for shipping to a
central laboratory for protein and cystine determinations.
Using this method, leukocyte cystine is nearly undetectable
in normal subjects (0–0.12umoles (half-cystine/gram cell
protein)whereasheterozygoteshaveabout4timesthisvalue,
and cystinotic levels are about ﬁfty times normal, usually
ranging from 1–10umoles half-cystine/g protein.
2.Cystinosisand the Renal Fanconi’sSyndrome
In 1924, Lignac expanded on the observations of Aberhalden
to point out that children with cystinosis often present
with profound rickets [2]. In 1931, Fanconi was the ﬁrst to
perceive that cystinosis is associated with urinary wasting
of substances that are normally reabsorbed during their
passage through the renal tubules [3] .T h ef u l lp i c t u r eo f
this tubulopathy was expanded by DeToni, who explained
the rickets by documenting urinary phosphate wasting [4]
and Debre et al. who noted excretion of organic acids [5].
Fanconi’s further contribution to the subject came in 1936,
when he recognized the similarities between these cases,
referred to the disease as nephrotic-glycosuric dwarﬁsm with
hypophosphatemic rickets and suggested that the organic
acids found in the urine might be amino acids [6]. In
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Figure 2: Growth curve for a cystinotic child. (1) Growth velocity
fall oﬀ at 4–6 months of age improves with salt supplements
and increased ﬂuid volume delivered by a nasogastric tube. (2)
Slowing of growth velocity at 17–19 months of age is improved by
introduction of indomethacin to reduce electrolyte losses by 25–
30%.
1947, Dent characterized the urinary amino acid and protein
proﬁle of cystinotic children and proved that this was due to
defective absorption [7].
Unlike most other tissues which deal with the ubiquitous
turnover of cellular proteins, the renal proximal tubule
must also contend with the enormous daily load of low-
molecular-weight proteins contained in glomerular ﬁltrate.
These proteins undergo endocytotic uptake as they pass
through the proximal tubular lumen and are delivered to
lysosomes where they are degraded into their constituent
amino acids. Interestingly, newborns may appear normal
at birth and exhibit only mild amino aciduria. However,
between 4 and 6 months of age proximal tubulardysfunction
emerges, and infants fall oﬀ their growth curves (Figure 2).
By a year of age, apoptotic cell death causes progressive
atrophy of the proximal tubule, leading to the “swan neck”
deformity described by Clay et al. [8].
With the recognition of the renal Fanconi’s syndrome,
clinicians were able to extend the lives of cystinotic children
by replacing the crucial constituents lost in urine. These
therapeutic strategies have been developed over many years
a n dh a v eb e e nr e v i e w e db yo t h e r s[ 9], but several points are
worthy of note as follows.
(1) Hypophosphatemic rickets can be largely reversed by
divided daily oral supplements of sodium phosphate.
However, since phosphate salts are cathartic, the dose
should be gradually increased to 50–100mg/kg/day
phosphate over several weeks so that peak serum
phosphate levels (at 1 hour) are eventually brought
into the low-normal range. Furthermore, since oralInternational Journal of Nephrology 3
p h o s p h a t ea c t sa sac a l c i u mb i n d e ra n ds t i m u l a t e s
parathyroid hormone release, the ﬁnal oral phos-
phate dose should be matched by enough calcitriol
(10–50ug/kg/day) to ensure adequate uptake of
dietary calcium to maintain normal levels of intact
parathyroid hormone.
(2) Repair of chronic volume contraction is important
for growth. In small infants, this nearly always
requires placement of a nasogastric tube and, even-
tually, a gastrostomy tube. Estimates of urine volume
and natriuresis in timed urine collections can then be
used to guide ﬂuid intake and salt supplementation
and normalize plasma renin level.
(3) In small infants, indomethacin (1.5–3mg/kg/day)
may reduce urine volume and electrolyte losses by
about one-third. However, it should be accompanied
by omeprazole or another modern proton pump
inhibitor.Emmahassuggestedthatitmaybeprudent
to discontinue indomethacin as the child approaches
school age and has reported that introduction of
an ACE inhibitor at this time may prolong renal
function [10].
(4) Proximal renal tubular acidosis and urinary potas-
sium losses may require large oral supplements of
bicarbonate and potassium that may cause vomiting.
Correction is best achieved by a mix of sodium bicar-
bonate, potassium citrate, and potassium chloride.
Although the early years are dominated by the impact
of the renal Fanconi’s syndrome, untreated children develop
a number of nonrenal manifestations. Hair color is usually
blond or much lighter than that in the parents. However, it is
unclear whether this represents a genetically linked trait or a
disturbance of pigmentation, since many examples of black
hair have been reported. Corneal crystal deposition becomes
increasingly evident during the second year of life. While
some children need little therapy, photophobia is common,
and most patients begin to use sunglasses in early childhood.
Since tear production may be diminished, lubricant eye
drops are helpful. If blepharospasm begins to interfere with
daily life, children should be treated with topical cysteamine
eye drops. Although corneal crystals do not seem to disturb
visual acuity, severe untreated corneal involvement may lead
to band keratophy which can obscure vision. Progressive
dysfunction of the thyroid gland may become evident within
the ﬁrst decade, and elevation of serum TSH levels should
prompt oral thyroxine replacement.
3.CystinosisandProgressiveRenal Failure
In 1952, Bickel and Smellie pointed out that cystinotic
children develop inexorable loss of glomerular ﬁltration
despite treatment of the renal Fanconi’s syndrome [11]. In
untreated cystinotics, multinucleated podocytes are seen in
glomeruli [12, 13], and tubular proteinuria is overshadowed
by progressive focal segmental glomerulosclerosis associated
with nephrotic-range proteinuria and progressive renal








Figure 3: Cystine-depleting eﬀect of cysteamine. Cystine forms
mixedsulﬁdeswithintralysosomalcystinethatareabletoeﬄuxinto
the cytoplasm via alternative lysosomal channels.
much, leading Royer to remark in his textbook of Pediatric
Nephrology that children with cystinosis usually survive
until the age of about 10–12 years, when they succumb to
end-stage renal failure [15].
It was about this time, however, that advances in
pediatric renal transplantation allowed the ﬁrst cystinotic
children to leap past this roadblock. In 1970, Mahoney et al.
reported excellent renal allograft survival in four cystinotic
children and pointed out that, as expected, there was no
evidence of recurrent cystinosis in the allograft [16]. As
cystinotics develop end-stage renal disease, they may have
heavy proteinuria and high urine volumes. However, the
incidence of graft thrombosis is not diﬀerent than that in the
general population, and children are accustomed to drinking
large volumes prior to transplantation [14]. Thus, it is not
entirely evident that they need pretransplant nephrectomise,
and this decision should be approached carefully.
4.CystinosisandCysteamine
Inthelate1960s,investigatorsattheUSNationalInstitutesof
Health discovered that the accumulation of cystine in patient
tissues was due to a defect in eﬄux of free cystine from lyso-
somes isolated from cystinotic ﬁbroblasts or leukocytes [17–
22]. Patrick and Lake demonstrated ascertained by electron
microscopy that the intracellular crystals in cystinotic tissues
were surrounded by lysosomal membranes [23]. Reasoning
that progressive tissue injury might be ameliorated if cystine
could be mobilized from the lysosomes; Schneider reported
in 1976 that the sulfhydryl reagent, cysteamine, could react
with intralysosomal cystine, permitting eﬄux of resulting
mixed disulﬁdes via alternative channels in the lysosomal
membrane (Figure 3)[ 24]. Gahl went on to show that
protracted oral therapy with cysteamine-depleted organ
cystine [25] and organized a North American trial of
cysteamine that demonstrated slowing of progressive renal
failure, particularly in those children who began therapy
before the age of two years and were adherent to the
prescribed dose (1.3gm/m2, divided qid) [26]. In a retro-
spective review of 100 adults with cystinosis, Gahl reported
that late complications of cystinosis (diabetes mellitus,4 International Journal of Nephrology
muscle wasting, hypothyroidism, pulmonary dysfunction,
and death) decreased with time on cysteamine therapy [27].
Despite the apparent beneﬁts of long-term cysteamine
therapy, there is no question that strict adherence to the
medication is diﬃcult. For that reason, leukocyte cystine
should be monitored on a regular basis. In early childhood,
when most patients receive cysteamine via nasogastric
tubes or under parental supervision, leukocyte cystine falls
abruptly to about 15% of baseline values which is close to
the heterozygous range and usually below 0.5umoles half-
cystine/g protein (Figure 4). However, following a variable
“honeymoon period,” mean leukocyte cystine tends to
drift gradually upwards, and the number of frankly non-
compliant patients increases signiﬁcantly in adolescence
(Goodyer, unpublished). In 2010, Dohil et al. reported their
experience comparing enteric-coated cysteamine (25mg/kg)
with the standard cysteamine bitartrate (47mg/kg) [28].
Theydemonstratedequivalentmeanserumcysteaminelevels
and noted no signiﬁcant clinical deterioration while taking
the enteric-coated preparation twice a day for 1-2 years [28].
A phase II clinical trial of enteric-coated cysteamine (Raptor
Pharmaceutical) is now nearing completion, and it is hoped
that adherence will be improved by the twice-a-day dosing
schedule.
5. Adult Complications of Cystinosis
With the advent of renal transplantation and cysteamine
therapy, the natural history of cystinosis has been shifted
(Figure 5). Nesterova and Gahl have reviewed the late com-
plications of cystinosis, including myopathy, encephalopa-
thy, diabetes mellitus, male infertility, retinal degeneration,
hypothyroidism and coronary artery calciﬁcations [29].
In general, the severity of these complications correlates
with the number of years without cysteamine treatment.
However, cysteamine therapy does not prevent the need
for eventual renal transplantation and cannot eliminate the
many debilitating complications that arise in adulthood. In
1988, Sonies et al. reported the case of a 20-year-old male
with distal muscle atrophy and progressive loss of the ability
to sit without support, but sensation and nerve conduction
were intact. In a review of 101 posttransplant patients,
about half had evidence of signiﬁcant myopathy, particularly
debilitating was the loss of pharyngeal musculature causing
dysphagia and oromotor dysfunction interfering with speech
[30]. Myopathy contributes to light exercise intolerance and
pulmonary dysfunction as well.
Trauner et al. has recently described the subtle spatial
perception deﬁcit in children with cystinosis [31]. Young
cystinotic children might have subtle learning disabilities
that could be overcome with learning interventions that
diminish reliance on spatial perception skills. After the age
of twenty, untreated cystinotic adults may develop cortical
dysfunction with progressive confusion, tremor, and seizures
[32]. Broyer et al. reported that only 5% of patients have
evidence of encephalopathy at age 23, but this increases
rapidly to 45% by age 27 [33]. Interestingly, Broyer et
















































Figure 4: Leukocyte monitoring of leukocyte cystine levels in 50
Canadian children with nephropathic cystinosis. Introduction of
oral cysteamine therapy (1.3g/m2/day in four divided doses) in
early childhood achieves a rapid reduction of trough 6–8 hours
after a single dose. Following a variable “honeymoon period,” mean
leukocyte cystine gradually drifts upwards as compliance decreases.
Cystine levels return to baseline when stopped brieﬂy for transplant
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Figure 5: Natural history of untreated cystinosis.
improve some manifestations of the encephalopathy [33].
Mueller described a cystinotic woman who developed some
memory loss with mild cortical atrophy at age of 29
evident by magnetic resonance imaging. With introduction
of cysteamine, cerebral function and cortical atrophy were
stable, but distal myopathy continued to progress. If this case
is representative, it may be diﬃcult to avert muscle wasting
in adult cystinosis. Although growth hormone has been used
to accelerate somatic growth in cystinotic children, its eﬀects
on muscle wasting in the adult have not been studied.
Experience with cystinosis in adulthood oﬀers several
management lessons. Firstly, that cysteamine therapy should
be started as early as possible and continued throughout
life; renal transplantation does not diminish the need for
continued therapy, and even late introduction of cysteamine
may provide clinical beneﬁts. Secondly, adherence to cys-
teamine therapy is especially diﬃcult during teenage years
and strategies to improve compliance and facilitate the
transition to adult care systems are crucial. Thirdly, the many
forms of organ dysfunction that arise during adulthood
warrant specialized cystinosis-speciﬁc outpatient care units,
since management usually requires expertise well beyond the
skills of the nephrologist who may preside over care at the
time renal transplantation is needed.International Journal of Nephrology 5
6. Cystinosisand Stem CellTherapy
In 2009, Syres et al. reported successful hematopoietic stem
cell therapy of cystinosis in mice [34]. Cells from a wild-
type mouse infused into CTNS (−/−) recipients were able
to home to damaged tissues, reducing tissue cystine levels
by 90% and normalizing organ function. This remarkable
observation raises this immediate question of whether a
similar strategy might be feasible in humans. One scenario
would involve standard bone marrow transplantation, in
which bone marrow stem cells from a healthy donor are
infused into the cystinotic patient who has undergone
marrow-ablative chemotherapy. Alternatively, the patient’s
own stem cells might be corrected by transfection with
the wild-type CTNS gene in vitro and reinfused. Although
there remain a number of practical problems to solve before
human trials are considered, work in the mutant mouse
modelhasopenedanewhopeforthetreatmentofcystinosis.
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